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Objectives The study sought to identify factors associated with increased risk of thrombosis after Fontan.
Background The Fontan procedure is the culmination of staged palliation for patients with univentricular physiology. Throm-
bosis is an important complication after this procedure.
Methods An international multicenter randomized controlled trial of acetylsalicylic acid versus warfarin for thrombopro-
phylaxis after the Fontan procedure was conducted in 111 patients, and did not show a significant difference
regarding thrombotic complications. We performed a secondary analysis of this previously published manuscript
to identify factors associated with thrombosis in this population. Standardized prospective data collection in-
cluded independent adjudication of all events.
Results At 2.5 years after randomization, time-related freedom from thrombosis was 69% (all venous, no arterial
events), with 28% of thrombosis presenting with clinical signs or events. Hazard of thrombosis was highest
immediately after Fontan with a gradual increase in risk during late follow-up. In multivariable models, fac-
tors associated with higher risk of thrombosis were pulmonary atresia with intact ventricular septum (haz-
ard ratio [HR]: 3.64, 95% confidence interval [CI]: 1.04 to 12.70, p  0.04), pulmonary artery distortion
(HR: 2.35, 95% CI: 0.96 to 5.73, p  0.06), lower pre-operative unconjugated bilirubin (HR: 0.84 mol/l,
95% CI: 0.72 to 0.99, p  0.04), use of central venous lines for10 days or until hospital discharge (HR: 17.8,
95% CI: 3.97 to 79.30, p 0.001), and lower FiO2 24 h after the procedure (HR: 0.67/10%, 95% CI: 0.45 to 1.00, p
0.06). Patients on warfarin who consistently achieved minimum target international normalized ratio levels or those on
acetylsalicylic acid had a decrease in risk of thrombosis compared with patients who often failed to meet target interna-
tional normalized ratio level (HR: 3.53, 95% CI: 1.35 to 9.20, p 0.01).
Conclusions More favorable thromboprophylaxis strategies are needed in light of the difficulties in controlling warfarin ther-
apy and the high prevalence of thrombosis in this population (International Multi Centre Randomized Clinical
Trial of Anticoagulation in Children Following Fontan Procedures; NCT00182104) (J Am Coll Cardiol 2013;61:
346–53) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1023Thrombosis and thromboembolic events are a major cause
of morbidity and mortality after the Fontan procedure.
Multiple observational studies with various designs and
duration of follow-up have reported the prevalence of
thrombosis after the Fontan procedure to be between 1%
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procedure, likely related to the surgery and the impact of
cardiopulmonary bypass itself (10). There also appears to be
an increasing risk over the long term after Fontan (11),
culminating in a substantial proportion of late-term (10
years) mortality in this population being associated with
thromboembolic complications (7,12,13).
Multiple studies have explored the effectiveness of throm-
boprophylaxis strategies in this population (3,14); consensus
has yet to be achieved on the matter. This has led to
institutional variation in practices, with some centers using
low-intensity antiplatelet-based therapy and others using high-
intensity anticoagulation-based therapy (15). Therapy is se-
lected on the basis of physician discretion, with decision
making being driven by weighing the perceived thrombosis risk
for a given patient against the inherent risks of long-term
anticoagulation (14). In this context, an evidence-based strat-
ification of patients according to thrombosis risk would be a
useful tool in selecting the intensity of thromboprophylaxis
strategy warranted in these patients.
Few risk factors have been confirmed from observational
studies, including the presence of bilateral bidirectional cavo-
pulmonary shunts, a blind-ended pulmonary artery stump, a
hypoplastic chamber with stasis of flow, and previous throm-
bosis (2,16). An atriopulmonary or Kawashima Fontan con-
nection type, presence of thrombogenic material, dilated
atrium, arrhythmias, ventricular dysfunction, patent fenestra-
tion, and protein-losing enteropathy have all also been hypoth-
esized as potential risk factors in this population (7,17).
Increased presence of thrombophilic risk factors have been
described, with uncertain clinical meaning, both before and
after Fontan (18–23). As a secondary analysis of a prospective,
multicenter randomized clinical trial of thromboprophylaxis
strategies for the first 2 years after the Fontan procedure (24),
we sought to identify factors associated with increased risk of
thrombosis in this population.
Methods
This is a secondary analysis of a previously published random-
ized controlled trial. Complete details of study intervention and
trial results have been previously reported (24).
Study subjects. Patients were recruited between 1998 and
2003 from 6 institutions (242 patients screened, 208 eligi-
ble, 111 enrolled and randomized). All patients who under-
went Fontan procedure at participating institutions were
eligible for inclusion in the trial. Exclusion criteria were a
recognized indication for long-term anticoagulation; patient
characteristics increasing the risk of hemorrhagic complica-
tions; known contraindication for heparin, warfarin, or
acetylsalicylic acid (ASA); and the inability to supervise
therapy because of social or geographic circumstances.
Randomization and study intervention. Randomization
(centrally performed but stratified by center) was performed
immediately after completion of the Fontan procedure.
Subjects were randomized to either warfarin therapy (0.1mg/kg titration to achieve and
international normalized ratio
(INR) of 2 to 3 with heparin
lead-in) or ASA (5 mg/kg/day)
for a 2-year period after the pro-
cedure. INR monitoring was
prescribed to be performed at
least every 2 to 3 weeks for stable
patients and more frequently for
patients with dosing challenges.
Proportion of INR measurement
within the target range was cali-
brated to risk and then included
in risk factor analyses. On the basis of this analysis, we
defined controlled warfarin therapy as 30% of INR
measurements within the target range (INR 2 to 3).
Measurements. Demographics, underlying cardiac anat-
omy, previous interventions and complications, and previ-
ous and current medical therapy were abstracted for each
patient from their respective medical records, including data
regarding the Fontan procedure and post-operative compli-
cations. Patients were asked to undergo clinical evaluation at
3, 6, 12, 18, and 24 months after randomization and
whenever it was clinically indicated regardless of whether
they were still taking their assigned study medication and/or
had reached a study endpoint. Thrombotic events (venous
or arterial) were the study primary endpoint. Thrombosis
was defined as the appearance of a space-occupying lesion
on ultrasound within the cardiovascular system (mild lam-
inar thickening of the internal surface of the Fontan
pathway was not included) or the occurrence of a clinical
event known to be strongly associated with thrombus
(stroke, pulmonary embolism). Thrombosis with clinical
presentation or clinical events known to be strongly associ-
ated with thrombus (cardioembolic stroke, pulmonary em-
bolism), were captured for all patients, regardless of whether
planned echocardiography or TEE were performed. Trans-
thoracic echocardiography and TEE were sought twice at 3
and 24 months post-Fontan procedure. An independent
central adjudication committee reviewed all clinically driven
and routine echocardiograms. All thrombosis and major
adverse clinical events were adjudicated by an expert panel.
Statistics. Data are presented as mean  SD, median with
minimum and maximum value, and frequency, as appropri-
ate. Time-related risk of thrombosis was modeled in para-
metric hazard regression model (maximum likelihood
method for parameter estimation), which allows for risk of
thrombosis to be divided in up to 3 distinct phases of risk,
although only an early and a late phase were present in this
study. Because of the limited number of events, risk hazard
analysis was performed assuming a single phase of risk. A
stepwise variable selection strategy was used (forward entry,
only variables with univariable p values 0.10 eligible for
entry) to create a multivariable parametric survival regres-
Abbreviations
and Acronyms
ASA  acetylsalicylic acid
CI  confidence interval
CNS  central nervous
system
HR  hazard ratio
INR  international
normalized ratio
TEE  transesophageal
echocardiographysion model. All analyses presented in this study combined
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9.2 (SAS Institute, Cary, North Carolina).
Results
Study population. A total of 111 patients (64% male,
average age at Fontan 4.8  2.8 years) were enrolled.
Primary diagnoses were tricuspid atresia (n  21, 19%),
double inlet left ventricle (n  21, 19%), double outlet right
ventricle (n  12, 11%), pulmonary atresia with intact
ventricular septum (n  6, 5%), unbalanced atrioventricular
septal defect (n  10, 9%), hypoplastic left heart (n  17,
15%), and other/multiple anomalies (n  24, 22%). The
majority of patients had previous cardiac catheterization
(n  63, 56%), and 24 (22%) had a previous Norwood
operation. A total of 72% of patients had a previous
bidirectional cavopulmonary shunt, 14% had a bilateral
cavopulmonary shunt, and 14% had undergone the Damus-
Kaye-Stansel procedure. The majority of patients had a
Fontan procedure utilizing an extracardiac conduit (n  95,
85%) with GORE-TEX baffle (n  81, 73%) and fenes-
tration (n  69, 62%).
Original trial results. The original trial found no differ-
ence in risk of thrombosis between patients randomized to
warfarin (n  54) versus those randomized to ASA (n 
57); hazard ratio [HR]: 1.35, 95% confidence interval [CI]:
0.62 to 3.00, p  0.45) at the 2 years study endpoint (24).
Patient characteristics and compliance with study proce-
dures and measurements were similar between both exper-
imental groups (24). Because of the lack of differences, all
analyses presented in this study combined both groups.
Study follow-up and compliance with study procedures.
Of the 111 patients enrolled in this study, 3 patients died
or were withdrawn from the study prior to study end or
reaching primary outcomes. A further 3 patients died or
were withdrawn from the study after reaching the study
primary outcome. All other patients attended the final study
visit within 30 months of enrollment. Complete accrual of
clinical events was obtained, 81% of patients underwent at
least 1 TEE (69% having the 3-month TEE, 61% having
the 24-month TEE) and 48% having both protocol TEEs.
Prevalence of thrombosis. At 2.5 years after randomiza-
tion, time-related freedom from thrombosis was 69% (all
venous, no arterial events), with 28% of thrombosis present-
ing with clinical signs or events. Time-related risk of
thrombosis was divided in 2 distinct phases—an early phase
of risk spanning the first 6 months after the Fontan
procedure, followed by late phase spanning the subsequent
2 years (Fig. 1). The risk of thrombosis associated with a
clinical presentation was highest immediately following
Fontan surgery, but persisted with a gradual increase
throughout the study period.
Compliance with study drug assignment and protocol.
Early discontinuations of study drug were more frequent in
the warfarin group (19% vs. 9%), with patients assigned to
ASA therapy spending 92% of expected study days on thestudy drug compared to 84% for patients assigned to
warfarin (p 0.02). A total of 2,166 INR monitoring values
were available in 45 patients (INR monitoring results were
not available for 9 patients), of which 41% were below target
range (2), 44% were within target range, and 15% were
above target range (3). According to our classification
30/45 patients (66%) assigned to warfarin had controlled
INR (30% of INR values within target) and 15 of 45
patients (33%) had uncontrolled INR (30% within of INR
values within target). None of the factors evaluated in this
study was found to be associated with increased risk of
poorly controlled warfarin therapy.
Factors associated with increased risk of thrombosis. Pa-
tient characteristics at the time of randomization are pre-
sented in Table 1, stratified according whether they devel-
oped thrombosis during follow-up. Because of the limited
number of events, risk factor analysis was performed by
combining the early and the late phase into a single phase of
Figure 1 Freedom From and Hazard of Thrombosis
Over Time in Patients After Fontan Surgery
Regarding freedom from (A) and hazard of (B) thrombosis, all patients are
included from study randomization up to first thrombotic event, study with-
drawal, or end of study, no censoring for drug discontinuation. Dotted lines rep-
resent 95% confidence interval. A high early-phase hazard is present followed
by a lower, but increasing, hazard of thrombosis in the late phase.risk. Factors associated with thrombosis in multivariable
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multivariable models, factors associated with higher risk of
thrombosis included pulmonary atresia with intact ventric-
ular septum (HR: 3.64, 95% CI: 1.04 to 12.70, p  0.04),
ulmonary artery distortion before Fontan procedure (HR:
.35, 95% CI: 0.96 to 5.73, p  0.06), lower pre-operative
nconjugated bilirubin (HR: 0.84 mol/l, 95% CI: 0.72 to
0.99, p  0.04), post-operative use of central venous lines
for 10 days or until discharge (HR: 17.8, 95% CI: 3.97 to
79.30, p  0.001), and lower FiO2 at 24 h post-surgery
(HR: 0.67, 95% CI: 0.45 to 1.00, p  0.06). Patients on
arfarin who achieved target INR levels 30% of time or
hose on acetylsalicylic acid had a 3.5-fold decrease in risk of
hrombosis compared patients who often failed to meet
arget INR level (HR: 3.53, 95% CI: 1.35 to 9.20, p 0.01)
Fig. 2). The difference in risk between controlled warfarin
nd ASA was not statistically significant (HR: 0.34, 95%
I: 0.10 to 1.13, p  0.08). There was no association
etween presence of pulmonary atresia or pulmonary artery
istortion and location of thrombosis. Year of enrolment,
ge at Fontan surgery, interventions prior to Fontan, pre-
ious thromboembolic complications, pre-operative hema-
ological laboratory values, or hemodynamics and type of
ontan connection were not associated with risk of
hrombosis.
iscussion
he current study found that there is a substantial imme-
iate risk of thrombosis which diminishes but persists over
he first 2.5 years after Fontan procedure. Overall time-
elated risk of thrombosis as found in this study was
omewhat different from that reported before in population-
ased observational studies (3,11,17), which have showed a
10% surgery-related thrombosis prevalence and then an
ngoing risk over time. Prevalence of surgery-related
hrombosis has previously been reported (10) at approxi-
ately 10% for low-risk surgeries such as the Fontan
rocedure. Because patients with surgery-related thrombo-
is are often required to be on anticoagulation for an
xtended period of time, these patients would not have been
ligible for this study. Our rate of thrombosis after the
mmediate high-risk surgical period in enrolled patients is
onsistent with previously reported studies (11). Of note, all
hromboses were found in the venous system. This is
onsistent with previous reports where thrombosis is typi-
ally located within both pulmonary and systemic venous
ystems (2,25). However, no thromboembolic event, such as
entral nervous system (CNS) or pulmonary or coronary
rtery embolism, were noted in our subjects. There was
o routine CNS surveillance, so clinically silent events
ay have been missed. Previous studies have reported the
ncidence of stroke to be as high as 19% post-Fontan
2,7,26 –28).
Factors associated with thrombosis in this population
ncluded anatomical characteristics, pre-operative clinical dtatus and post-operative outcomes, and anticoagulation
anagement. Anatomical factors disturbing laminar blood
ow are known to increase the risk of thrombosis in children
ith congenital heart disease by creating physiological dead
nds and areas of sluggish flow promoting thrombus for-
ation (2,16). Other identified risk factors have been
ssociated with increased propensity to clot, either by
romoting platelet activation through inflammation (low
xygen saturation), impaired metabolism of coagulation
roteins secondary to liver dysfunction (low bilirubin)
29–31), and/or damage to vascular walls (central venous
ines). Most of these risk factors have been reported previously,
oth in the Fontan population and in other populations with
ongenital heart disease (10). Of particular importance is the
ncreased risk of thrombosis associated with prolonged use of
entral venous lines (10). Aggressive strategies for early line
emoval and interventions aimed at reducing the prevalence of
ine-related thrombosis might have an important impact on the
ccurrence of early thrombosis in this population.
The most important finding of this study is the decreased
isk of thrombosis associated with properly controlled war-
arin therapy or ASA compared with warfarin therapy with
30% of INR monitoring within the target range. Diffi-
ulties in controlling warfarin therapy are well documented
n pediatric patients (32,33). Individual response to warfarin
aries between patients on the basis of physiological and
enetic factors. Furthermore, warfarin dosing is known to
e affected by a multitude of drug and food interactions.
revious studies have shown minimal anticoagulation activ-
ty with INR 2, and almost nonexistent anticoagulation
ctivity when INR falls below 1.5 (34).
Our study showed an increased risk of thrombosis for
atients with poorly controlled warfarin therapy. Clinically,
his finding has multiple implications; it may provide an
xplanation why previous studies have found inconsistent
esults regarding the efficacy of strategies for thrombopro-
hylaxis in Fontan patients. The earliest nonrandomized
omparison reported better event-free survival for patients
eceiving warfarin versus no anticoagulation (3). Three
mall case series with few events (2 studies, n  4; 1 study,
 10) concluded that there was no influence of antico-
gulation (6,28,35). The trial on which this study is based
ound no differences between ASA and warfarin (24).
inally, a recent single-center observational study of throm-
oprophylaxis in single ventricle patients, in which warfarin
as favored for the majority of patients, found that
arfarin-based thromboprophylaxis was associated with a
ignificant reduction of thrombosis risk compared with no
hromboprophylaxis and to ASA-based thromboprophy-
axis (11).
The other important clinical consideration raised by these
esults regards the risk-benefit ratio for these patients. Since
isk reduction for thrombosis is minimal in patients with
oorly controlled warfarin therapy, the risk of anticoagula-
ion becomes unwarranted. Future studies should try to
etermine patient characteristics are associated with diffi-
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n No Thrombosis n Thrombosis
Univariable HR
(95% CI) p Value
Treatment and randomization
Treated with aspirin 86 45 (52%) 25 12 (48%) 0.74 (0.33–1.09) 0.45
Controlled warfarin 86 27 (31%) 25 3 (12%) 0.34 (0.10–1.13) 0.08
Uncontrolled warfarin 86 8 (9%) 25 7 (28%) 3.70 (2.81–4.58) 0.004
Warfarin monitoring, no data 86 6 (7%) 25 3 (12%) 2.17 (0.64–7.33) 0.21
Demographics
Gender (female) 86 27 (31%) 25 13 (52%) 0.50 (0.23–1.10) 0.09
Older age at surgery, yrs 86 4.7 2.6 25 4.7 3.9 1.05 (0.93–1.19) 0.45
Greater weight (kg) at surgery 86 17.0 6.8 25 18.1 8.8 1.01 (0.96–1.06) 0.86
Primary diagnosis
Tricuspid atresia 86 16 (19%) 25 5 (20%) 1.03 (0.39–2.76) 0.95
Double inlet ventricle 86 17 (20%) 25 4 (16%) 0.80 (0.27–2.36) 0.69
Double outlet right ventricle 86 8 (9%) 25 4 (16%) 1.60 (0.54–4.72) 0.39
Pulmonary atresia with intact ventricular septum 86 3 (3%) 25 3 (12%) 3.31 (0.98–11.18) 0.05
Unbalanced atrioventricular septal defect 86 8 (9%) 25 2 (8%) 0.86 (0.20–3.65) 0.83
Hypoplastic left heart syndrome 86 14 (16%) 25 3 (12%) 0.95 (0.28–3.20) 0.93
Previous cardiac surgical procedures
Cardiac catheter/interventional procedures 86 48 (56%) 25 15 (60%) 1.10 (0.49–2.46) 0.81
Pulmonary artery banding 86 15 (17%) 25 5 (20%) 1.09 (0.41–2.91) 0.86
Patent ductus arteriosus ligation or clipping 86 16 (19%) 25 3 (12%) 0.76 (0.23–2.57) 0.66
Systemic-pulmonary shunt 86 49 (57%) 25 16 (64%) 1.25 (0.55–2.83) 0.60
Atrial septostomy 86 28 (33%) 25 7 (28%) 0.87 (0.36–2.09) 0.75
Norwood operation 86 18 (21%) 25 6 (24%) 1.52 (0.60–3.85) 0.38
DKS procedure for subaortic stenosis 86 13 (15%) 25 3 (12%) 0.96 (0.28–3.22) 0.94
Bidirectional cavopulmonary shunt 86 61 (71%) 25 19 (76%) 1.30 (0.52–3.28) 0.57
Bilateral cavopulmonary shunt 86 12 (14%) 25 3 (12%) 0.83 (0.25–2.77) 0.76
Classic Glenn shunt 86 7 (8%) 25 2 (8%) 1.03 (0.24–4.42) 0.96
Coarctation repair 86 6 (7%) 25 2 (8%) 1.37 (0.32–5.88) 0.67
Branch pulmonary artery repair 86 12 (14%) 25 3 (12%) 0.78 (0.23–2.61) 0.69
Previous thromboembolic event 86 13 (15%) 25 2 (8%) 0.57 (0.13–2.44) 0.45
Pre-operative assessment (bloodwork)
Hemoglobin (10 g/l) 86 166 20 25 167 20 1.00 (0.98–1.02) 0.75
Platelet count (109/l) 86 280 79 25 292 82 1.00 (1.00–1.01) 0.64
Activated partial thromboplastin time, s 79 36.3 17.9 21 32.4 3.6 0.97 (0.91–1.04) 0.38
International normalized ratio (0.1) 75 1.18 0.51 18 1.05 0.11 0.82 (0.57–1.18) 0.29
Prothrombin time, s 41 12.5 4.5 13 13.4 1.4 1.03 (0.88–1.20) 0.74
Albumin, g/l 33 39.8 6.4 17 42.3 3.1 1.05 (0.96–1.16) 0.30
AST, U/l 20 37 (26–163) 8 30 (18–45) 0.88 (0.79–0.99) 0.03
ALT, U/l 31 20 (9–33) 17 20 (11–33) 1.02 (0.95–1.11) 0.56
Bilirubin (conjugated), mol/l 29 0 (0–3) 16 0 (0–11) 1.14 (0.92–1.41) 0.23
Bilirubin (unconjugated), mol/l 31 10 (5–24) 17 9 (0–19) 0.90 (0.79–1.01) 0.07
Pre-operative assessment (cardiac catheterization)
Mean pulmonary artery pressure, mm Hg 84 11 3 25 11 2 0.96 (0.81–1.13) 0.62
Mean left atrial pressure, mm Hg 64 6 2 23 7 2 1.10 (0.93–1.29) 0.26
Right atrial pressure, mm Hg 66 6 2 22 6 3 1.03 (0.87–1.23) 0.70
Systolic aortic pressure, mm Hg 83 84 12 24 81 12 0.98 (0.94–1.02) 0.27
Mean aortic pressure, mm Hg 81 59 13 22 59 9 1.01 (0.97–1.04) 0.72
SVC oxygen saturation, % 77 69 10 22 69 9 0.99 (0.96–1.03) 0.78
Pulmonary artery oxygen saturation, % 72 70 8 22 70 7 0.99 (0.94–1.04) 0.62
Left atrium oxygen saturation, % 51 86 19 19 91 9 1.03 (0.98–1.08) 0.25
Aorta oxygen saturation, % 79 87 5 22 86 6 0.98 (0.90–1.07) 0.69
Oxygen saturation in room air, % 81 81 8 25 78 9 0.98 (0.95–1.02) 0.39
Sinus rhythm 86 77 (90%) 25 23 (92%) 1.33 (0.31–5.67) 0.70
Current atrioventricular valve regurgitation 86 12 (14%) 25 4 (16%) 0.64 (0.24–1.70) 0.36
Current pulmonary artery distortion 86 15 (17%) 25 8 (32%) 2.25 (0.96–5.28) 0.06Continued on the next page
confid
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The thromboprophylaxis strategy in these patients should
be carefully selected taking this information into account.
ContinuedTable 1 Continued
n No Thro
Fontan procedure
Type of Fontan procedure 86
Lateral tunnel/total cavopulmonary connection 15 (17%
Extracardiac conduit 71 (83%
Type of baffle or conduit used 86
GORE-TEX 64 (74%
Homograft 22 (26%
Size of baffle or conduit used, mm 79 19.0
Fenestration 86 55 (64%
Size of fenestration, mm 55 4.5
Patch repair of pulmonary artery stenosis 86 5 (6%)
Atrial septostomy 86 7 (8%)
Division of main pulmonary artery 86 6 (7%)
Perioperative assessment
Cardiopulmonary bypass time (10 min) 86 106
Aortic cross-clamp time (10 min) 86 0 (0–7
Minimum temperature on bypass, °C 81 30.6
Inotropes support duration (10 h) 86 22 (0–1
Vasodilators support duration (10 h) 86 12 (0–6
Central venous line 10 days or at CCU discharge 86 4 (5%)
Mean blood pressure, mm Hg 86 69
Central venous/pulmonary artery pressure, mm Hg 83 14
Left atrial pressure, mm Hg 58 8
Arterial oxygen saturation, % 82 91
Inspired oxygen (FiO2) (10%) 64 41
Post-operative assessment
Persistent effusion 86 39 (45%
Persistent chylothorax 86 16 (19%
Total parenteral nutrition 86 5 (6%)
Creatinine (10 mol/l) 84 40 (28–
AST (20 U/l) 38 59 (16–
ALT (20 U/l) 50 26 (11–
Duration of ventilation (10 h) 86 10 (3–1
Duration of intensive care unit stay, days 84 2 (1–7
Central venous lines 10 days 86 4 (5%)
Values are n (%), mean  SD, or median (5th, 95th percentile).
ALT  alanine aminotrasnferase; AST  aspartate transaminase; CCU  critical care unit; CI 
Factors Associated WithThrombosis in Multivariable Regression ModelTable 2 Fac ors Associated WithThrombosis in Multivariable Regression Model
Variables
Multivariable HR
(95% CI) p Value
Pulmonary atresia with intact ventricular septum 3.64 (1.04–12.7) 0.04
Pulmonary artery distortion 2.35 (0.96–5.73) 0.06
Lower preoperative bilirubin (unconjugated),
mol/l
0.84 (0.72–0.99) 0.04
Central venous line 10 days or at
CCU discharge
17.8 (3.97–79.3) 0.001
Lower inspired oxygen (FiO2) at 24 h after
surgery (10%)
0.67 (0.45–1.00) 0.06
Uncontrolled warfarin thromboprophylaxis 3.53 (1.35–9.20) 0.01Abbreviations as in Table 1.Patients who have started warfarin-based thromboprophy-
laxis but who are unable to maintain adequate INR levels
may be better off receiving ASA therapy alone. New oral
anticoagulants, which have been shown in adult trials to be
noninferior regarding efficacy while being more stable,
easier to dose, and overall safer than warfarin (36–39),
might be a solution for this population, however, as their
safety in children is undetermined, future comparative trials
would be required (40).
Study limitations. This study must be viewed in light of
some limitations. Children in our study did not undergo
CNS imaging, and clinically silent events may have been
missed. Not all patients had both TEEs as stipulated in the
protocol. Therefore, some asymptomatic thrombi might not
have been identified. Because of the limited number of
events available for analysis we had to collapse the 2
n Thrombosis
Univariable HR
(95% CI) p Value
25 0.27 (0.04–1.98) 0.20
1 (4%)
24 (96%)
25 0.67 (0.29–1.57) 0.36
17 (68%)
8 (32%)
22 19.4 2.5 1.02 (0.88–1.18) 0.80
25 14 (56%) 0.90 (0.40–1.99) 0.79
14 3.8 1.8 0.92 (0.78–1.09) 0.34
25 3 (12%) 1.86 (0.55–6.27) 0.31
25 2 (8%) 0.99 (0.23–4.20) 0.99
25 4 (16%) 1.81 (0.62–5.30) 0.28
25 102 42 0.99 (0.91–1.07) 0.78
25 0 (0–48) 0.85 (0.69–1.06) 0.14
23 31.3 3.7 1.04 (0.92–1.17) 0.55
25 24 (0–95) 0.99 (0.92–1.08) 0.88
25 11 (0–70) 1.14 (0.97–1.34) 0.11
25 3 (12%) 3.06 (0.91–10.29) 0.07
25 71 9 1.02 (0.98–1.05) 0.42
24 14 5 1.02 (0.93–1.11) 0.67
19 7 2 0.96 (0.83–1.12) 0.64
24 92 6 1.02 (0.96–1.08) 0.57
24 34 11 0.82 (0.59–1.14) 0.24
25 15 (60%) 1.79 (0.80–3.99) 0.16
25 5 (20%) 1.18 (0.44–3.15) 0.75
25 3 (12%) 2.98 (0.89–10.03) 0.08
25 44 (25–80) 0.97 (0.82–1.13) 0.67
15 51 (29–2,617) 1.03 (0.90–1.16) 0.70
21 36 (16–540) 1.01 (0.99–1.03) 0.18
25 11 (3–143) 1.00 (0.94–1.08) 0.89
25 2 (1–7) 0.98 (0.82–1.16) 0.81
25 3 (12%) 2.97 (0.45–16.42) 0.19
ence interval; DKS  Damus-Kaye-Stansel; HR  hazard ratio; SVC  superior vena cava.mbosis
)
)
)
)
3.0
)
1.8
55
8)
4.2
65)
0)
11
5
3
9
18
)
)
105)
2,658)
1,142)
90)
)identified phases of risk (early and late) into 1 and perform
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optimal. Additionally, details of INR monitoring were not
available for all patients included in the warfarin group;
therefore, our classification of controlled vs. uncontrolled
warfarin applied only to a subset of patients. Finally,
although our study outlines the importance of achieving
target levels of anticoagulation with warfarin, the determi-
nation of whether a given patient is likely to have warfarin
dosing difficulties requires a lengthy exposure to warfarin
and consequently a lengthy increased-risk period for throm-
bosis. The results of this post hoc secondary analysis must be
viewed as hypothesis generating, although they also suggest
superiority of well-controlled warfarin over ASA, which is
in contrast to the primary intention to treat analysis reported
for the clinical trial (24). Considering the fact that we could
not identify factors associated with poorly controlled war-
farin therapy in these patients, ASA might be the best
current strategy to prevent thrombosis for the overall pop-
ulation. Future studies, including both laboratory assess-
ments and genetic evaluations, may be helpful to determine
which patients are at increased likelihood of having prob-
lems with warfarin dosing.
Conclusions
This study demonstrated that patients with Fontan physi-
ology have a high and ongoing risk of thrombosis, which is
highest in the immediate perioperative period, followed by
a lower chronic risk that may gradually increase with
longer-term follow-up. Underlying physiology and post-
Figure 2 Freedom From Thrombosis Over Time Stratified
by Thromboprophylaxis Choice and Effectiveness
All patients included from study randomization up to first thrombotic event,
study withdrawal, or end of study, no censoring for drug discontinuation. Con-
trolled warfarin was defined as 30% of international normalized ratio (INR)
within target over the study period. Patients on warfarin who consistently
achieved target INR levels 30% of the time or those on acetylsalicylic acid
had a 3.5-fold decrease in risk of thrombosis compared patients who often
failed to meet target INR level (hazard ratio: 3.53, 95% confidence interval:
1.35 to 9.20, p  0.01), and difference in risk between controlled warfarin
and ASA was not statistically significant (hazard ratio: 0.34, 95% confidence
interval: 0.10 to 1.13, p  0.08).operative clinical status were associated with increased riskof thrombosis. This study also outlined the importance of
achieving minimum therapeutic targets when using warfarin
for thromboprophylaxis. Future studies should focus on
identifying factors associated with failure of warfarin ther-
apy and evaluating the effectiveness and safety of new oral
anticoagulants.
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